ImmunoCellular seeks next level leader after CEO resignation 'mess'
This article was originally published in Scrip
ImmunoCellular Therapeutics founder, chief scientific officer and chairman John Yu told Scrip that the Los Angeles-based cancer vaccine developer is "looking for a leader to take the company to the next level" since president and CEO Manish Singh resigned "to pursue other opportunities."
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.